Compare AGM & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | TNDM |
|---|---|---|
| Founded | 1987 | 2006 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | AGM | TNDM |
|---|---|---|
| Price | $172.05 | $14.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 19 |
| Target Price | ★ $215.00 | $28.00 |
| AVG Volume (30 Days) | 75.2K | ★ 2.0M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | $25.97 | $8.11 |
| Revenue Next Year | $12.21 | $11.85 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $136.57 | $10.00 |
| 52 Week High | $210.64 | $29.65 |
| Indicator | AGM | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 27.50 |
| Support Level | $167.06 | $13.24 |
| Resistance Level | $177.14 | $15.75 |
| Average True Range (ATR) | 5.83 | 1.35 |
| MACD | -0.55 | -0.53 |
| Stochastic Oscillator | 15.72 | 2.65 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.